LICENSE AND COLLABORATIVE ARRANGEMENTS	12 Months Ended
Dec. 31, 2018
LICENSE AND COLLABORATIVE ARRANGEMENTS
LICENSE AND COLLABORATIVE ARRANGEMENTS	LICENSE AND COLLABORATIVE ARRANGEMENTS Ironwood Pharmaceuticals, Inc. In July 2011, the Company entered into a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. (Ironwood Agreement) granting Ironwood a license for worldwide rights to certain patents and other intellectual property rights to the Company’s Acuform drug delivery technology for IW 3718, an Ironwood product candidate under development for refractory GERD. During the third quarter of 2018, the Company recognized, within Royalties and Milestones on the Company’s Consolidated Statements of Operations, a $5.0 million milestone payment related to the dosing of the first patient in a Phase 3 trial for IW-3718. The Company will receive additional contingent milestone payments upon the occurrence of certain development milestones and royalties on net sales of the product, if approved. Slan Medicinal Holdings, Ltd. In November 2017, the Company entered into definitive agreements (Slán Agreements) with Slán Medicinal Holdings Limited and certain of its affiliates (Slán) pursuant to which the Company acquired Slán’s rights to market the specialty drug long-acting cosyntropin in the U.S. and Canada. As outlined in the Slán Agreements, each party will support the development, including clinical development, of the licensed product and efforts to obtain regulatory approval of the initial NDA. The Slán Agreements also detail commercialization activities which are included in the commercialization plan. Subsequent to approval of the initial NDA, Assertio and Slán will share in the net sales of long acting cosyntropin for a 10-year period (after which time the product will revert back to Slán). The Company has committed to invest $15.0 million in the collaboration with Slán for the commercialization efforts of long-acting cosyntropin. As of the December 31, 2018 the Company had incurred $4.6 million of development expenses which are reimbursable by Slán and have been recognized within Prepaid and Other Assets on the Company’s Consolidated Balance Sheet. The Company also recognized expenses of $2.25 million which are payable to Slán following the initial NDA filing in December 2018.

LICENSE AND COLLABORATIVE ARRANGEMENTS

Ironwood Pharmaceuticals, Inc.

In July 2011, the Company entered into a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. (Ironwood Agreement) granting Ironwood a license for worldwide rights to certain patents and other intellectual property rights to the Company’s Acuform drug delivery technology for IW 3718, an Ironwood product candidate under development for refractory GERD. During the third quarter of 2018, the Company recognized, within Royalties and Milestones on the Company’s Consolidated Statements of Operations, a $5.0 million milestone payment related to the dosing of the first patient in a Phase 3 trial for IW-3718. The Company will receive additional contingent milestone payments upon the occurrence of certain development milestones and royalties on net sales of the product, if approved.

Slan Medicinal Holdings, Ltd.

In November 2017, the Company entered into definitive agreements (Slán Agreements) with Slán Medicinal Holdings Limited and certain of its affiliates (Slán) pursuant to which the Company acquired Slán’s rights to market the specialty drug long-acting cosyntropin in the U.S. and Canada. As outlined in the Slán Agreements, each party will support the development, including clinical development, of the licensed product and efforts to obtain regulatory approval of the initial NDA. The Slán Agreements also detail commercialization activities which are included in the commercialization plan. Subsequent to approval of the initial NDA, Assertio and Slán will share in the net sales of long acting cosyntropin for a 10-year period (after which time the product will revert back to Slán). The Company has committed to invest $15.0 million in the collaboration with Slán for the commercialization efforts of long-acting cosyntropin. As of the December 31, 2018 the Company had incurred $4.6 million of development expenses which are reimbursable by Slán and have been recognized within Prepaid and Other Assets on the Company’s Consolidated Balance Sheet. The Company also recognized expenses of $2.25 million which are payable to Slán following the initial NDA filing in December 2018.